Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 15;10:947–954. doi: 10.2147/COPD.S80022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Suzuki et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Changes in clinical variables after treatment with inhaled budesonide/formoterol.

Notes: Results for pulmonary function parameters, radiological parameters, and CAT scores were compared between pretreatment and 3 months after therapy with budesonide/formoterol using nonparametric Wilcoxon rank sum tests. Bars indicate standard errors.

Abbreviations: CAT, chronic obstructive pulmonary disease assessment test; %CSA <5, percentage of total cross-sectional area of pulmonary vessels less than 5 mm²; FEV₁, forced expiratory volume in 1 second; LAV%, percentage of low attenuation volume; PEF, peak expiratory flow; Post, 3 months after treatment with budesonide/formoterol; Pre, pretreatment with budesonide/formoterol; WA%, percentage of wall area.